Other Events ·
Moleculin Biotech, Inc. received a Staff Determination Letter from Nasdaq on September 15, 2026, notifying the company…
MBRXMoleculin Biotech, Inc.
Moleculin Biotech, Inc. received a Staff Determination Letter from Nasdaq on September 15, 2026, notifying the company that its common stock is not in compliance with the minimum bid price requirement because the closing price remained below $1.00 for 30 consecutive business days ending September 11, 2026. The company is ineligible for a standard 180-day compliance period due to having effected a 1-for-25 reverse stock split on December 1, 2025. Moleculin intends to request a hearing before the Nasdaq Hearings Panel, which will stay any delisting action pending the decision while shares continue trading. The company operates in the biotechnology industry and develops therapies for cancer.